We were thrilled to see national media coverage of the Molecular Screening & Therapeutics (MoST) study – the leading Australian program delivering molecular screening and trials matching to advanced cancer patients.

The incredibly powerful stories of patients like Pauline and Peter are a reminder of the importance of establishing local clinical trials to provide early access to medicines, bolster the Australian healthcare system and improve the lives of cancer patients.

The support of our partners Steve Burnell at Minderoo Foundation, MoST clinical trial lead Dr Oliver Klein and NHMRC Clinical Trials Centre helps bring novel treatment access to all Australians – including those living in regional areas.